Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials

2017 ◽  
Vol 162 (3) ◽  
pp. 409-417 ◽  
Author(s):  
Luca F. Valle ◽  
Surbhi Agarwal ◽  
Kathleen E. Bickel ◽  
Haley A. Herchek ◽  
David C. Nalepinski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Randomized Trials ◽  
Early Stage ◽  
Meta Analysis ◽  
Breast Conservation ◽  
Early Stage Breast Cancer ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

scholarly journals No Difference in Overall Survival and Non-Breast Cancer Deaths after Partial Breast Radiotherapy Compared to Whole Breast Radiotherapy—A Meta-Analysis of Randomized Trials

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2309
Author(s):  
Jan Haussmann ◽  
Wilfried Budach ◽  
Stefanie Corradini ◽  
David Krug ◽  
Balint Tamaskovics ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Randomized Trials ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer ◽  
Effect Sizes ◽  
Breast Irradiation ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

Purpose/objective: Adjuvant radiotherapy after breast conserving surgery is the standard approach in early stage breast cancer. However, the extent of breast tissue that has to be targeted with radiation has not been determined yet. Traditionally, the whole breast was covered by two opposing tangential beams. Several randomized trials have tested partial breast irradiation (PBI) compared to whole breast irradiation (WBI) using different radiation techniques. There is evidence from randomized trials that PBI might result in lower mortality rates compared to WBI. We aimed to reassess this question using current data from randomized trials. Material/methods: We performed a systematic literature review searching for randomized trials comparing WBI and PBI in early stage breast cancer with publication dates after 2009. The meta-analysis was performed using the published event rates and the effect sizes for overall survival (OS), breast cancer-specific survival (BCSS), and non-breast cancer death (NBCD) as investigated endpoints. Analysis of subgroups using different radiation techniques was intended. We used hazard ratios (HR) and risk differences (RD) to estimate pooled effect sizes. Statistical analysis was performed using the inverse variance heterogeneity model. Results: We identified eleven studies randomizing between PBI and WBI. We did not find significant differences in OS (n = 14,070; HR = 1.02; CI-95%: 0.89–1.16; p = 0.810, and n = 15,203; RD = −0.001; CI-95%: −0.008–0.006; p = 0.785) and BCSS (n = 15,203; RD = 0.001; CI-95%: −0.002–0.005; p = 0.463). PBI also did not result in a significant decrease of NBCD (n = 15,203; RD = −0.003; CI-95%: −0.010–0.003; p = 0.349). A subgroup analysis by radiation technique also did not point to any detectable differences. Conclusion: In contrast to a previous assessment of mortality, we could not find a detrimental effect of WBI on OS or NBCD. A longer follow-up might be necessary to fully assess the long-term mortality effects of PBI compared to WBI.

scholarly journals Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Linwei Wang ◽  
Min Sun ◽  
Shuailong Yang ◽  
Yuanyuan Chen ◽  
Tian Li
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Therapeutic Option ◽  
Meta Analysis ◽  
Intraoperative Radiotherapy ◽  
Recurrence Risk ◽  
Early Stage Breast Cancer ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

ObjectiveIntraoperative radiotherapy (IORT) in early-stage breast cancer has been studied over the years. However, it has not been demonstrated whether IORT is more suitable as a therapeutic option for early-stage breast cancer than whole breast radiotherapy (WBRT). Therefore, we performed a meta-analysis to compare the efficacy and safety of IORT to those of WBRT as therapeutic options for early-stage breast cancer patients receiving breast-conserving surgery (INPLASY2020120008).MethodsPubMed, Embase, and Cochrane Library databases were searched from inception to October 2021. Computerized and manual searches were adopted to identify eligible randomized control trials from online databases. Risk ratio (RR) and 95% confidence intervals (CI) were calculated by random-effect models to assess the relative risk. Potential publication bias was quantified by Begg’s and Egger’s tests.ResultsBased on our inclusion criteria, 10 randomized control trials involving 5,698 patients were included in this meta-analysis. This meta-analysis showed that the IORT group was associated with a higher local recurrence risk (RR = 2.111, 95% CI, 1.130–3.943, p = 0.0191), especially in the long-term follow-up subgroup or published after 2020 subgroup or Caucasian subgroup (RR = 2.404, 95% CI, 1.183–4.885, p = 0.0154). Subgroup analysis showed that the IORT group had a higher recurrence risk than the WBRT group in the polycentric randomized controlled trial subgroup (RR = 1.213, 95% CI, 1.030–1.428, p = 0.0204). Pooled analysis showed that there was no statistically significant difference in overall survival, recurrence-free survival, distant metastasis-free survival, and cancer-specific survival between IORT and WBRT groups. Additionally, the risk of skin toxicity was reduced, but the incidences of fat toxicity, edema, and scar calcification were significantly increased in the patients who underwent IORT in comparison to those who underwent WBRT.ConclusionThis meta-analysis revealed that IORT was not a better alternative to WBRT. More large-scale and well-designed clinical trials with longer follow-up periods are encouraged to further investigate the value of IORT.Systematic Review Registrationhttps://inplasy.com/inplasy-2020-12-0008/.

scholarly journals Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

2019 ◽  
Vol 12 (8) ◽  
pp. 815-824 ◽  
Author(s):  
Anne Julienne Genuino ◽  
Usa Chaikledkaew ◽  
Due Ong The ◽  
Thanyanan Reungwetwattana ◽  
Ammarin Thakkinstian
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab

Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis

2014 ◽  
Vol 146 (2) ◽  
pp. 235-244 ◽  
Author(s):  
Francisco E. Vera-Badillo ◽  
Marc Napoleone ◽  
Alberto Ocana ◽  
Arnoud J. Templeton ◽  
Bostjan Seruga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer

The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1050-1050
Author(s):  
Rodrigo Ramella Munhoz ◽  
Allan Andresson Lima Pereira ◽  
Andre Deeke Sasse ◽  
Paulo Marcelo Hoff ◽  
Tiffany A. Traina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Ovarian Function ◽  
Early Stage ◽  
Meta Analysis ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Lhrh Agonists ◽  
Function Preservation

Effect of race on completion of chemotherapy in early stage breast cancer: A systematic review and meta-analysis.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18749-e18749
Author(s):  
Angela K Green ◽  
Emeline Aviki ◽  
Sujata Patil ◽  
Victoria Susana Blinder
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document